Growth Metrics

Gilead Sciences (GILD) Total Current Liabilities (2016 - 2026)

Gilead Sciences filings provide 17 years of Total Current Liabilities readings, the most recent being $11.8 billion for Q4 2025.

  • On a quarterly basis, Total Current Liabilities fell 1.59% to $11.8 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $11.8 billion, a 1.59% decrease, with the full-year FY2025 number at $11.8 billion, down 1.59% from a year prior.
  • Total Current Liabilities hit $11.8 billion in Q4 2025 for Gilead Sciences, down from $12.3 billion in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $14.0 billion in Q2 2023 to a low of $8.6 billion in Q1 2022.
  • Median Total Current Liabilities over the past 5 years was $11.3 billion (2022), compared with a mean of $11.2 billion.
  • Biggest five-year swings in Total Current Liabilities: soared 51.45% in 2023 and later fell 22.79% in 2024.
  • Gilead Sciences' Total Current Liabilities stood at $11.6 billion in 2021, then fell by 3.21% to $11.2 billion in 2022, then grew by 0.38% to $11.3 billion in 2023, then grew by 6.42% to $12.0 billion in 2024, then decreased by 1.59% to $11.8 billion in 2025.
  • The last three reported values for Total Current Liabilities were $11.8 billion (Q4 2025), $12.3 billion (Q3 2025), and $11.2 billion (Q2 2025) per Business Quant data.